These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 31377920)
1. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920 [TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466 [TBL] [Abstract][Full Text] [Related]
3. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Houillier C; Taillandier L; Dureau S; Lamy T; Laadhari M; Chinot O; Moluçon-Chabrot C; Soubeyran P; Gressin R; Choquet S; Damaj G; Thyss A; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Tanguy ML; Al Jijakli A; Morel P; Bourquard P; Moles MP; Chauchet A; Gastinne T; Constans JM; Langer A; Martin A; Moisson P; Lacomblez L; Martin-Duverneuil N; Delgadillo D; Turbiez I; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C; J Clin Oncol; 2019 Apr; 37(10):823-833. PubMed ID: 30785830 [TBL] [Abstract][Full Text] [Related]
4. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G; Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815 [TBL] [Abstract][Full Text] [Related]
5. Cognitive functions in survivors of primary central nervous system lymphoma. Correa DD; DeAngelis LM; Shi W; Thaler H; Glass A; Abrey LE Neurology; 2004 Feb; 62(4):548-55. PubMed ID: 14981169 [TBL] [Abstract][Full Text] [Related]
6. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038 [TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537 [TBL] [Abstract][Full Text] [Related]
8. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112 [TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
10. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348 [TBL] [Abstract][Full Text] [Related]
11. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings? de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167 [TBL] [Abstract][Full Text] [Related]
13. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608 [TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853 [TBL] [Abstract][Full Text] [Related]
15. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma. Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506 [TBL] [Abstract][Full Text] [Related]
16. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience. Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330 [TBL] [Abstract][Full Text] [Related]
17. Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom? Bairey O; Shargian-Alon L; Siegal T Acta Haematol; 2021; 144(4):389-402. PubMed ID: 33242855 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Ferreri AJ; Crocchiolo R; Assanelli A; Govi S; Reni M Leuk Lymphoma; 2008 Nov; 49(11):2042-7. PubMed ID: 19021047 [TBL] [Abstract][Full Text] [Related]
19. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Ferreri AJ; Illerhaus G Blood; 2016 Mar; 127(13):1642-9. PubMed ID: 26834241 [TBL] [Abstract][Full Text] [Related]
20. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]